In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

EHJ – Cardiovascular Pharmacotherapy

Specific Focus on Clinical Cardiovascular Pharmacology

 

The European Heart Journal – Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal reports on the interpretation and integration of new scientific developments  to improve the pharmacological treatment of patients with cardiovascular disease.

It publishes original articles on clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

 

Fast Facts

  • Editor-in-chief: Stefan Agewall FESC, NO
  • Current volume: 7 (year 2021)
  • Issues per subscription: 6
  • Impact Factor 2020: 6.617

 

Editor in chief History

Name Start Date End Date
 Professor Stefan Agewall 01/01/2015  
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blind, peer review by experienced international experts.


Most recent articles from EHJ-CVP

21 Sep 2021
More knowledge about atrial fibrillation, still we need to learn
Author(s):Agewall S.
04 Aug 2021
Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: a focus on the net clinical benefit
Author(s):Kazem N, Sulzgruber P, Niessner A.
06 Sep 2021
Call for emergency action to limit global temperature increases, restore biodiversity, and protect healthWealthy nations must do much more, much faster*
Author(s):Atwoli L, Baqui A, Benfield T, et al.
29 Jun 2021
Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Author(s):Buryachkovskaya L, Lomakin N, Melkumyants A, et al.